文献速递胸部肿瘤

新提出的非小细胞肺癌TNM分类中M描述符的预后影响

Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non-Small Cell Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2016-11-17

本研究在2011至2014年间连续纳入的1024例IV期非小细胞肺癌患者中验证新提出的M描述符的预后价值。按新分类,M1a、M1b、M1c组分别有262例(25.6%)、152例(14.8%)、610例(59.6%),中位总生存期分别为22.5、17.8、13.6个月(p < 0.001)。多因素调整后,M1b组总生存期较M1a组显著缩短(风险比=1.30;95%置信区间:1.03-1.65,p = 0.03),M1c组较M1b组显著缩短(风险比=1.57;95%置信区间:1.28-1.93,p < 0.001)。

要点

  • 新M描述符将IV期NSCLC分为M1a、M1b、M1c三组,各组中位总生存期分别为22.5、17.8、13.6个月(p < 0.001)。
  • 多因素调整后,M1b组总生存期较M1a组显著缩短(风险比=1.30;95%置信区间:1.03-1.65,p = 0.03)。
  • M1c组总生存期较M1b组显著缩短(风险比=1.57;95%置信区间:1.28-1.93,p < 0.001),且该差异在病理和分子亚型中呈一致趋势。

核心结论

  • 新提出的M描述符在IV期非小细胞肺癌患者中具有预后价值。

研究设计与样本

  • 研究分析了2011至2014年间连续肺癌数据库中接受治疗的1024例IV期非小细胞肺癌患者,使用新提出的M分期进行分类和生存比较,并调整其他临床协变量及进行亚组分析。

主要发现

  • 根据新M描述符,M1a、M1b、M1c组分别有262例(25.6%)、152例(14.8%)、610例(59.6%)。
  • M1a、M1b、M1c组的中位总生存期分别为22.5、17.8、13.6个月(p < 0.001)。
  • 调整其他协变量后,Cox比例风险回归显示M1b组总生存期较M1a组显著缩短(风险比=1.30;95%置信区间:1.03-1.65,p = 0.03)。
  • M1c组总生存期较M1b组显著缩短(风险比=1.57;95%置信区间:1.28-1.93,p < 0.001)。
  • 这些差异在病理和分子亚型中显示一致趋势。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The International Association for the Study of Lung Cancer recently proposed new M descriptors for the next edition of the TNM classification for NSCLC, subdividing the current M1b category into two subcategories: M1b, which indicates a solitary extrathoracic metastasis in a single organ, and M1c, which indicates multiple extrathoracic metastasis. The purpose of this study was to validate the prognostic value of the newly proposed M descriptors in an independent cohort with multivariate and subgroup analysis. METHODS: A total of 1024 patients in a consecutive lung cancer database who had stage IV NSCLC treated between 2011 and 2014 were analyzed. Newly proposed M staging was used for classification and comparison of survival. Adjustment for other clinical covariates and subgroup analysis was conducted. RESULTS: According to the newly proposed M descriptors, 262 patients (25.6%), 152 patients (14.8%), and 610 patients (59.6%) were classified into the subgroups M1a, M1b, and M1c, respectively. The median overall survival times were 22.5, 17.8, and 13.6 months for the M1a, M1b, and M1c groups, respectively (p < 0.001). After adjustment for other covariates, Cox proportional hazards regression revealed statistically significantly shorter overall survival for the M1b group than for the M1a group (hazard ratio = 1.30; 95% confidence interval: 1.03-1.65, p = 0.03) and for the M1c than the M1b group (hazard ratio = 1.57; 95% confidence interval: 1.28-1.93, p < 0.001). These differences showed a consistent tendency regardless of pathologic and molecular subtypes. CONCLUSIONS: The newly proposed M descriptors have prognostic value in patients with stage IV NSCLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Shin J, Keam B, Kim M, et al. Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non-Small Cell Lung Cancer. J Thorac Oncol. 2016. PMID: 27867003. doi:10.1016/j.jtho.2016.11.2216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。